A Phase I/II, Dose-Escalation and Dose-Expansion Study of CS5006, in Participants With Advanced Solid Tumors

November 10, 2026 updated by: CStone Pharmaceuticals

A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5006, a Novel Antibody-Drug Conjugate Targeting ITGB4, in Participants With Advanced Solid Tumors

This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS5006 in participants with advanced solid tumors. The study comprises of a Phase I dose escalation and Phase II dose expansion.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

In Phase I, participants with specified advanced epithelial solid tumors will be enrolled to establish the MTD, if any, and tentative RP2D(s) of CS5006. The specified advanced epithelial solid tumors included but not limited non-small cell lung cancer (NSCLC), colorectal cancer (CRC), squamous cell carcinoma of head and neck (HNSCC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), cervical cancer (CC), esophageal squamous cell carcinoma (ESCC) , endometrial cancer, ovarian cancer (OC), renal cell carcinoma (RCC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), biliary tract cancer (BTC), gastric cancer (GC), pancreatic cancer(PDAC) and prostate cancer(PCa).

In Phase II, participants with selected advanced solid tumors - including locally advanced or metastatic non-small cell lung cancers (AGA [actionable genomic alterations] negative NSCLC, Cohort 1; EGFR-mutant NSCLC, Cohort 2; NSCLC with actionable driver alterations other than EGFR-sensitive mutations, Cohort 3; colorectal cancer (CRC), Cohort 4; squamous cell carcinoma of head and neck (HNSCC), Cohort 5; urothelial carcinoma (UC), Cohort 6; cervical cancer (CC), Cohort 7; esophageal squamous cell carcinoma (ESCC), Cohort 8 - will be enrolled to further assess the efficacy, safety, tolerability, pharmacokinetics of CS5006 at the tentative RP2D(s).

Study Type

Interventional

Enrollment (Estimated)

310

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • New South Wales
      • North Ryde, New South Wales, Australia, 2109
        • Macquarie University
        • Principal Investigator:
          • John Park, Dr
      • Randwick, New South Wales, Australia, 2031
        • Scientia Clinical Research Ltd
        • Principal Investigator:
          • Charlotte lemech, Dr
    • Victoria
      • Clayton, Victoria, Australia, 3168
        • Monash Medical Centre
        • Principal Investigator:
          • Sophia Frentzas, Dr
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200123
        • Shanghai East Hospital
        • Principal Investigator:
          • Caicun Zhou

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Evidence of a personally signed and dated informed consent document.
  • Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Being ≥ 18 years of age on the day of signing informed consent.
  • Pathologically or cytologically confirmed, unresectable advanced solid tumors.
  • Participants must have at least one measurable lesion according to RECIST Version1.1.
  • Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
  • Adequate organ function.
  • Life expectancy ≥ 3 months.
  • Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 180 days after the last study drug administration

Exclusion Criteria:

  • Has disease that is suitable for local treatment administered with curative intent.
  • Has a history of a second malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
  • Known primary central nervous system (CNS) tumor or solid tumor CNS metastasis that is symptomatic, untreated, or requires therapy.
  • Has life-threatening bleeding event or severe bleeding within 3 months prior to first dose.
  • Has uncontrolled pleural effusion, pericardial effusion, or ascites.
  • Has immune deficient disease or received systemic immunosuppressive treatment.
  • Has intestinal obstruction,or history of inflammatory bowel disease,or chronic diarrhea.
  • Has history of (non-infectious) interstitial lung disease/pneumonitis that required steroids.
  • Has active infections requiring systemic therapy.
  • Has significant cardiovascular disease or cerebrovascular accident within specified timeframes prior to first dose.
  • Insufficient washout from prior anti-tumor therapy.
  • Received live vaccine within 28 days prior to first dose.
  • History of allogeneic organ or hematopoietic stem cell transplantation.
  • History of hypersensitivity to excipients of study drug or any monoclonal antibody.
  • Any toxic effects of prior therapy unresolved to Grade ≤1.
  • Pregnant or breastfeeding women.
  • Other acute or chronic medical or psychiatric conditions that may increase risk or interfere with study results, in the investigator's judgment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Dose Escalation

Participants will be administered escalating doses of CS5006.

CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).

Experimental: Dose Expansion

Participants will be administered the recommended dose(s) of CS5006 according to dose-escalation data.

CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
[Dose Expansion] Objective response rate (ORR) evaluated by investigators per RECIST v1.1
Time Frame: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation] The incidence and severity of adverse events (AEs)
Time Frame: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation] Maximum tolerated dose (MTD) of CS5006
Time Frame: Cycle 1 (Up to 21 Days)

Participants will receive CS5006 via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). The MTD will be determined, if any, by the number of participants who experience a dose limiting toxicity (DLT).

Cycle 1 (Up to 21 Days)
[Dose Escalation] Tentative recommended Phase II dose (RP2D) of CS5006
Time Frame: Up to approximately 2 years

The selection of tentative RP2D will be based on consideration of overall safety information together with available pharmacokinetic, pharmacodynamic, and efficacy data. The tentative RP2D may be the MTD or a lower dose within the tolerable dose range.

Up to approximately 2 years

Secondary Outcome Measures

Outcome Measure
Time Frame
[Dose Escalation] Objective response rate (ORR) evaluated by investigators per RECIST v1.1
Time Frame: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Area under the curve (AUC) of CS5007
Time Frame: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Duration of response (DOR) evaluated by investigators per RECIST v1.1
Time Frame: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Disease control rate (DCR) evaluated by investigators per RECIST v1.1
Time Frame: Up to approximately 2 years
Up to approximately 2 years
[Dose Expansion] The incidence and severity of adverse events (AEs)
Time Frame: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Maximum concentration (Cmax) of CS5006
Time Frame: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Time to maximum concentration (Tmax) of CS5006
Time Frame: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Elimination half-life (t1/2) of CS5006
Time Frame: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Clearance (CL) of CS5006
Time Frame: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Volume of distribution (Vz) of CS5006
Time Frame: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Trough concentration (Ctrough) of CS5006
Time Frame: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Accumulation ratio (R) of CS5006
Time Frame: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Number of participants with anti-CS5006 antibodies
Time Frame: Up to approximately 2 years
Up to approximately 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

July 1, 2029

Study Completion (Estimated)

July 1, 2029

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CS5006-101

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.